NELFCD and myeloid sarcoma: Based on these data, our results might explain, at least in part, why progressive MS patients developing a Th17 disease are nonresponsive to IFN-β and prompt us to evaluate whether the Th1/Th17 cytokine ratio might be used to predict therapy effectiveness.